The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2022Self-reported Perceptions and Self-reported Outcomes on Motor and Non-motor Symptoms in the Parkinson's Disease Continuum: A Systematic Review of Mixed Methods
Study Rationale: People are unique in the way they experience quality of life. Throughout the progression of Parkinson's disease, patients and their care partners have different perceptions of motor...
-
Parkinson’s Pathway Molecular Data Analysis Program, 2022Developing Biomarker Signatures of Parkinson’s Disease Using a Novel Progression Model
Study Rationale: Although Parkinson’s disease (PD) affects individuals differently, there are groups of people with PD who share similar features and whose disease changes similarly over time...
-
Target Advancement Program, 2022Assessing the Neuroprotective Factor REST/NRSF as a Therapeutic Target for Parkinson’s Disease
Study Rationale: Evidence suggests that a regulatory factor called REST (also known as NRSF) could promote the survival of neurons in neurodegenerative conditions. Studies have shown that this...
-
Target Advancement Program, 2022Assessing the Ability of Neuronal Modulators to Treat or Modify the Motor Symptoms of Parkinson’s Disease
Study Rationale: The dopamine-producing cells that are lost in Parkinson’s disease (PD) express a unique type of cell-surface protein called the M5 muscarinic acetylcholine receptor. The presence of...
-
Expanding Biological Understanding of Parkinson's Disease, 2022Investigation of the Role of PINK1 in Regulating Immune Signaling in Mitochondria
Study Rationale: Evidence is accumulating that the Parkin and PINK1, gene products whose activities are altered in Parkinson’s disease (PD), play a role in immune signaling. We previously identified a...
-
Therapeutic Pipeline Program, 2022Developing an Assay to Identify Glucocerebrosidase-enhancing Chaperones for the Treatment of Parkinson’s Disease
Study Rationale: Discovering genes associated with Parkinson’s disease (PD) facilitates the design of new treatment strategies for this disorder. Mutations in the glucocerebrosidase gene (GBA1) are...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.